Navigation Links
Potential new flu drugs target immune response, not virus
Date:7/21/2014

The seriousness of disease often results from the strength of immune response, rather than with the virus, itself. Turning down that response, rather than attacking the virus, might be a better way to reduce that severity, says Juliet Morrison of the University of Washington, Seattle. She and her collaborators have now taken the first step in doing just that for the H7N9 influenza, and their work has already led to identification of six potential therapeutics for this highly virulent strain. The research is published ahead of print in the Journal of Virology.

"We set out to characterize the response to the severe disease-causing H7N9 virus and compare it to responses elicited by other serious flu viruses in a mouse model of infection," says Morrison. That work involved determining which genes are turned on by this infection.

"We have found that viruses that cause severe illness, like H7N9 and the infamous 1918 virus, trigger gene expression signatures that are different from the signatures seen in milder infections," says coauthor and University of Washington colleague Michael Katze, in whose laboratory the work was performed. "Importantly, we can exploit these signatures for antiviral drug discovery," he adds.

The investigators then used a computational approach to identify potentially therapeutic drugs. They searched databases containing gene expression profiles of cultured human cells that had been treated with different drugs, in order to find those that were the reverse of expression profiles induced by the H7N9 flu virus, and noting the drugs that accomplished this, says Morrison. These drugs could potentially dampen the harmful host response, she says.

"Six of these drugs are FDA approved and could potentially be repurposed as H7N9 influenza therapeutics," says Morrison. "I believe that computational biology represents an exciting new way to study viruses and to discover drugs to fight them," says Morrison. A
'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... release is available in Spanish . , ... fertiliser for soils, for example or to reduce their acidity. ... (UPV/EHU) PhD research thesis was to study the effects of ... Waste Water Purification Plant) waste sludge on the chemical properties ...
... estrogen plus progestin, which women stopped taking in droves ... of breast cancer, may decrease their risk of colorectal ... issue of Cancer Epidemiology, Biomarkers and Prevention , ... "Compared to women who had never taken these ...
... Smart Search & Match, the,leading provider of high-performance ... has joined the company as Vice President of,Sales ... Mr. Sembhi is a veteran executive in ... recently President of 4G Identity Solutions, where he,was ...
Cached Biology News:Adding high doses of sludge to neutralize soil acidity not advisable 2Hormone therapy associated with reduced colorectal cancer risk 2
(Date:5/21/2015)... uBiome, the leading startup focused ... PicnicHealth, a healthcare company that collects and consolidates ... Bowel Disease (IBD) will receive a complementary PicnicHealth ... kit. Both companies were funded by Y Combinator ... more information on this partnership and how to ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... As part of its philanthropic partnership ... Health Foundation funded a $3.25 million project to relocate ... the most up-to-date features and technology. , The new ... 45 staff members will begin moving from the current ... coming days. , The current pharmacy has been ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... , , ST. JOSEPH, Mich., ... company, announced today that it launched a collaborative development project ... and leading academic centers as members. The 24-month project aims ... of different types of stem cells. The knowledge base will ...
... 1 According to a new,market research report, ,Global ... ), the,global autoimmune treatment market is expected to be ... 12.7% from 2009 to 2014. The North,American market is ... revenues. , Browse 100+ market ...
... ... the Center for Orthopedics in Sheffield Village, Ohio, just west of Cleveland, now offers ... for patients without an intact rotator cuff. Until now, these individuals -- who are ... live with the pain." , ...
Cached Biology Technology:GeneGo Kicks Off The MetaMiner Stem Cell Project With Industry and Academics 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 2Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 3Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 4
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
...
3M Imidazole Solution 125 ml...
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Biology Products: